What is the difference between GLP-1 (7-37) and Oxyntomodulin?

GLP-1 (7-37): Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways. Oxyntomodulin: Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.

Is GLP-1 (7-37) FDA approved?

GLP-1 (7-37) is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Oxyntomodulin FDA approved?

Oxyntomodulin is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is GLP-1 (7-37) administered in research settings?

In research settings, GLP-1 (7-37) is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Oxyntomodulin administered in research settings?

In research settings, Oxyntomodulin is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›GLP-1 (7-37) vs Oxyntomodulin

Peptide Comparison

GLP-1 (7-37) vs Oxyntomodulin

Both are Metabolic peptides.

GLP-1 (7-37)

GLP-1 fragment

Fat LossNot EvaluatedResearch Only

33 providers listed

Full GLP-1 (7-37) profile →

Oxyntomodulin

OXM

Fat LossInvestigationalResearch Only

No providers listed yet

Full Oxyntomodulin profile →

Bottom line

Oxyntomodulin carries stronger published evidence (RCT, 11 key studies) than GLP-1 (7-37) (RCT, 2); both are research compounds.

Quick Verdict

GLP-1 (7-37)

Evidence

Emerging Clinical

Oxyntomodulin

Evidence

Established Clinical

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Oxyntomodulin
Further along in FDA review	Oxyntomodulin
More provider options (33 vs 0)	GLP-1 (7-37)

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

GLP-1 (7-37)

Oxyntomodulin

Mechanism Family

Metabolic

Half-life

—

FDA Status

not evaluated

investigational

Admin Routes

subcutaneous, intravenous

Availability

Research Only

Providers

33 listed

None listed

Research Evidence

GLP-1 (7-37)

Emerging ClinicalRCT · 2 key studies · most recent 2026

Oxyntomodulin

Established ClinicalRCT · 11 key studies · most recent 2026

Research Citations

GLP-1 (7-37)

Cohort2026 · Protein Sci

Aggregation-driven expression of liraglutide precursors using engineered mini-tags in Escherichia coli.

RCT1999 · Diabetes Care

GLP-1 treatment of obese patients with type 2 diabetes mellitus: improvement of insulin responsiveness by red…

Oxyntomodulin

RCT2026 · Appetite

Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy…

RCT2026 · Appetite

Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy…

RCT2026 · Appetite

Effects of acute moderate-intensity continuous running on circulating oxyntomodulin concentrations in healthy…

RCT2005 · Diabetes

Oxyntomodulin reduces energy intake and adiposity in overweight and obese subjects

+7 more

About GLP-1 (7-37)

Binds GLP-1 receptors in the pancreas, gut, and brain. Stimulates glucose-dependent insulin secretion and suppresses glucagon. Central GLP-1 receptor activation reduces food intake via hypothalamic pathways.

Research Areas

appetite suppressioninsulin sensitivityblood glucose regulation

About Oxyntomodulin

Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.

Research Areas

appetite suppressionenergy expenditurefat oxidation

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

GLP-1 (7-37)

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Acute pancreatitisPregnancy (discontinue; not for use in pregnancy)Gallbladder disease / cholelithiasisDiabetic retinopathy complications (reported with GLP-1 receptor agonist use)Severe GI disease / gastroparesis / ileus riskHypoglycemia when combined with insulin or sulfonylureasAcute kidney injury secondary to volume depletion

Class-based (investigational)

Oxyntomodulin

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC)Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Known hypersensitivity to the drug or excipients

Warnings & Cautions

Class-based (investigational)

Find Providers

Where to source these peptides

Providers offering

GLP-1 (7-37)

33 listed

Browse directory →

Providers offering

Oxyntomodulin

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.